Table 3.

Molecular mechanisms underlying the effects of ERCC1 in cervical cancer.

Study/Reference	Treatments for cervical cancer	Experimental model	Main findings
Britten et al. (36)	Cisplatin resistance	Cervical carcinoma lines (HT137, HT155, HT172, HT180 and HT212)	There was a significant correlation between ERCC1 mRNA expression and cisplatin resistance in all cervical carcinoma lines (all P< 0.05), but such an association was not significant in ERCC1 protein expression (all P>0.05). It might be possible to identify cervical tumors likely to be resistant to cisplatin by examining pre-treatment ERCC1 mRNA levels.
Torii et al. (21)	Cisplatin and 5-FU	Uterine cervical adenocarcinoma cells (HCA-1 and TCO-2)	There was an association between ERCC1 expression and sensitivity to cisplatin in cervical adenocarcinoma cells. A cisplatin-resistant cell line HCA-1R showed a dramatically higher level of ERCC1 mRNA expression than the native cells. Co-administration of cisplatin and 5-FU showed the synergistic or additive effects via inhibiting of ERCC1 expression.
Almeida et al. (37)	Radiotherapy	CASKI and C33A cells	Absent or weak modulations of ERCC1 was detected after exposure to 1.8 Gy of radiotherapy in cell lines, which might be associated with the inhibition of the regulatory axis p53-EGFR-ERCC1. Increased expressions of ERCC1 (5/10 patients; P=0.0294) was found in malignant tissues after radiotherapy with the same radiation dose. This study showed that upregulation of ERCC1 may be part of a radioresistance mechanism in cervical cancer.

ERCC1, excision repair cross-complementation group1; EGFR, epidermal growth factor receptor.